Research from Dubai Hospital Yields New Findings on Hypovolemia [Efficacy and Safety of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Use during Ramadan Fasting: A Systematic Review].

A recent study conducted at Dubai Hospital examined the safety and efficacy of using Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors during Ramadan fasting for individuals with type 2 diabetes. The research found that while hypovolemia and a drop in estimated glomerular filtration rate (eGFR) were reported in some studies, the overall use of SGLT2 inhibitors during Ramadan appeared to be safe and well-tolerated. The study concluded that there were no significant clinical implications associated with the use of SGLT2 inhibitors during Ramadan fasting. [Extracted from the article]